Resisting resistance: Establishing new treatment options for CRPC patients

Shaunna Beedie; William D. Figg

doi:10.1080/15384047.2016.1139271

Resisting resistance: Establishing new treatment options for CRPC patients

Shaunna Beedie, William D. Figg^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Overcoming drug resistance in castrate resistant prostate cancer requires improved understanding of mechanisms by which resistance occurs, as well as new treatment options. A recent study published in Nature (Li et al. 2015) examines the mechanism of abiraterone activity, and reveals the bioactivity of a breakdown product with exciting repercussions for therapy regimes.

Original language	English
Pages (from-to)	337-338
Number of pages	2
Journal	Cancer Biology and Therapy
Volume	17
Issue number	4
DOIs	https://doi.org/10.1080/15384047.2016.1139271
State	Published - 2 Apr 2016
Externally published	Yes

Keywords

abiraterone
enzalutamide
prostate cancer
▵4-abiraterone

Access to Document

10.1080/15384047.2016.1139271

Cite this

@article{8e5998678f2640b0b059d0b1daf7d729,

title = "Resisting resistance: Establishing new treatment options for CRPC patients",

abstract = "Overcoming drug resistance in castrate resistant prostate cancer requires improved understanding of mechanisms by which resistance occurs, as well as new treatment options. A recent study published in Nature (Li et al. 2015) examines the mechanism of abiraterone activity, and reveals the bioactivity of a breakdown product with exciting repercussions for therapy regimes.",

keywords = "abiraterone, enzalutamide, prostate cancer, ▵4-abiraterone",

author = "Shaunna Beedie and Figg, {William D.}",

note = "Publisher Copyright: {\textcopyright}This article not subject to US copyright law.",

year = "2016",

month = apr,

day = "2",

doi = "10.1080/15384047.2016.1139271",

language = "English",

volume = "17",

pages = "337--338",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Resisting resistance

T2 - Establishing new treatment options for CRPC patients

AU - Beedie, Shaunna

AU - Figg, William D.

N1 - Publisher Copyright: ©This article not subject to US copyright law.

PY - 2016/4/2

Y1 - 2016/4/2

N2 - Overcoming drug resistance in castrate resistant prostate cancer requires improved understanding of mechanisms by which resistance occurs, as well as new treatment options. A recent study published in Nature (Li et al. 2015) examines the mechanism of abiraterone activity, and reveals the bioactivity of a breakdown product with exciting repercussions for therapy regimes.

AB - Overcoming drug resistance in castrate resistant prostate cancer requires improved understanding of mechanisms by which resistance occurs, as well as new treatment options. A recent study published in Nature (Li et al. 2015) examines the mechanism of abiraterone activity, and reveals the bioactivity of a breakdown product with exciting repercussions for therapy regimes.

KW - abiraterone

KW - enzalutamide

KW - prostate cancer

KW - ▵4-abiraterone

UR - http://www.scopus.com/inward/record.url?scp=84958793799&partnerID=8YFLogxK

U2 - 10.1080/15384047.2016.1139271

DO - 10.1080/15384047.2016.1139271

M3 - Article

C2 - 26828765

AN - SCOPUS:84958793799

SN - 1538-4047

VL - 17

SP - 337

EP - 338

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 4

ER -

Resisting resistance: Establishing new treatment options for CRPC patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this